knowledge -WSS

knowledge

author：hotspot 2025-09-30 19:26:50 - browse：51133

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Industry veterans launch new biotech VC with $310M

focus

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

What should King Charles tell the public about his cancer?

Medicare Advantage proposed rates disappoint insurers

Analysis of telehealth claims data suggest service duplication

What should King Charles tell the public about his cancer?

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Gilead might be held responsible for not developing a drug

Activists slam private health insurers over coverage restrictions

Key House Republican on health care plans exit from Congress

Affirmative action in medical school literally saved lives

How digital tools helped lower hypertension in marginalized patients

United colonoscopy coverage change 'may cost lives,' doctors say

KalVista pill reduced swelling 'attacks' caused by genetic disease

Hepatitis C has a cure — but many Americans still lack access to it

Chemotherapy drug shortage eases slightly but still widespread

hotspot

Bristol 'take

The Readout: Gilead, Bernie Sanders, and other pharma news

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Medical mystery: When a cough is not just a cough

Why did Pfizer dish out millions for a Super Bowl ad?

Bill would stop addiction treatment from triggering child abuse inquiry

knowledge

focus

Wikipedia

hotspot